Esperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Post Earnings of -$1.82 Per Share

Equities research analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings of ($1.82) per share for the current quarter, according to Zacks. Four analysts have made estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.20) and the highest estimate coming in at ($1.70). Esperion Therapeutics posted earnings per share of $4.32 during the same quarter last year, which indicates a negative year-over-year growth rate of 142.1%. The business is expected to issue its next quarterly earnings results on Monday, August 9th.

On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($10.52) per share for the current year, with EPS estimates ranging from ($11.35) to ($10.10). For the next financial year, analysts expect that the company will report earnings of ($5.64) per share, with EPS estimates ranging from ($9.00) to $0.55. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, May 4th. The biopharmaceutical company reported ($3.50) EPS for the quarter, missing analysts’ consensus estimates of ($2.08) by ($1.42). The business had revenue of $8.00 million during the quarter, compared to analyst estimates of $34.28 million. Esperion Therapeutics had a negative net margin of 66.86% and a negative return on equity of 629.88%. The business’s revenue was up 344.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.84) earnings per share.

ESPR has been the subject of several research analyst reports. Jefferies Financial Group cut Esperion Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the stock from $40.00 to $30.00 in a research report on Friday, February 12th. Morgan Stanley reduced their price objective on shares of Esperion Therapeutics from $30.00 to $22.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 5th. BTIG Research lowered their target price on shares of Esperion Therapeutics from $90.00 to $71.00 in a research report on Wednesday, May 5th. Needham & Company LLC reduced their price target on shares of Esperion Therapeutics from $150.00 to $134.00 and set a “strong-buy” rating for the company in a research report on Thursday, February 25th. Finally, Credit Suisse Group lowered their price target on Esperion Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a report on Wednesday, May 5th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $49.27.

In related news, major shareholder Target N. V. Biotech purchased 200,000 shares of the business’s stock in a transaction dated Wednesday, May 19th. The stock was bought at an average cost of $20.37 per share, with a total value of $4,074,000.00. Following the completion of the acquisition, the insider now directly owns 4,377,964 shares in the company, valued at approximately $89,179,126.68. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 7.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new stake in shares of Esperion Therapeutics during the 1st quarter worth about $18,182,000. Norges Bank purchased a new position in shares of Esperion Therapeutics during the fourth quarter valued at approximately $6,957,000. Morgan Stanley boosted its position in Esperion Therapeutics by 575.7% during the fourth quarter. Morgan Stanley now owns 235,411 shares of the biopharmaceutical company’s stock worth $6,122,000 after acquiring an additional 200,573 shares during the last quarter. Citigroup Inc. grew its stake in Esperion Therapeutics by 405.3% in the 1st quarter. Citigroup Inc. now owns 165,031 shares of the biopharmaceutical company’s stock worth $4,629,000 after acquiring an additional 132,369 shares during the period. Finally, Wasatch Advisors Inc. raised its holdings in Esperion Therapeutics by 3.0% in the 1st quarter. Wasatch Advisors Inc. now owns 4,118,085 shares of the biopharmaceutical company’s stock valued at $115,512,000 after acquiring an additional 120,075 shares during the last quarter. Institutional investors own 99.89% of the company’s stock.

NASDAQ ESPR traded up $1.26 during trading hours on Thursday, hitting $25.38. 410,637 shares of the stock were exchanged, compared to its average volume of 768,845. The company has a market cap of $715.51 million, a P/E ratio of -4.15 and a beta of 1.20. The stock has a 50-day moving average of $24.15. Esperion Therapeutics has a 12-month low of $18.01 and a 12-month high of $53.73.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Featured Story: Do closed-end mutual funds pay dividends?

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.